NCT03030001

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Ningbo Cancer Hospital · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.

Conditions

• Solid Tumor, Adult
• Advanced Cancer

Interventions

Type	Name	Description
BIOLOGICAL	PD-1 antibody expressing mesothelin specific CAR-T cells	Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.

Timeline

• Start date: 2017-02-15
• Primary completion: 2018-12-01
• Completion: 2019-02-01
• First posted: 2017-01-24
• Last updated: 2017-01-24

Locations

1 site across 1 country: China